Using Survival Analysis to Identify Risk Factors for Treatment Interruption among New and Retreatment Tuberculosis Patients in Kenya by Masini, Enos O. et al.
Macalester College
DigitalCommons@Macalester College
Faculty Publications Mathematics, Statistics, and Computer Science
10-4-2016
Using Survival Analysis to Identify Risk Factors for
Treatment Interruption among New and
Retreatment Tuberculosis Patients in Kenya
Enos O. Masini
Ministry of Health, Nairobi, Kenya
Omar Mansour
Macalester College, omar.mansour19@gmail.com
Clare E. Speer
Macalester College
Vittorio Addona
Macalester College, addona@macalester.edu
Christy L. Hanson
Macalester College, chanson5@macalester.edu
See next page for additional authors
Follow this and additional works at: http://digitalcommons.macalester.edu/mathfacpub
Part of the Mathematics Commons, and the Medicine and Health Sciences Commons
This Article is brought to you for free and open access by the Mathematics, Statistics, and Computer Science at DigitalCommons@Macalester College.
It has been accepted for inclusion in Faculty Publications by an authorized administrator of DigitalCommons@Macalester College. For more
information, please contact scholarpub@macalester.edu.
Recommended Citation
Masini EO, Mansour O, Speer CE, Addona V, Hanson CL, Sitienei JK, et al. (2016) Using Survival Analysisto Identify Risk Factors for
Treatment Interruption among New and Retreatment Tuberculosis Patients in Kenya. PLoS ONE 11(10): e0164172. doi:10.1371/
journal.pone.0164172
Authors
Enos O. Masini, Omar Mansour, Clare E. Speer, Vittorio Addona, Christy L. Hanson, Joseph K. Sitienei,
Hillary K. Kipruto, Martin Muhingo Githiomi, and Brenda Nyambura Mungai
This article is available at DigitalCommons@Macalester College: http://digitalcommons.macalester.edu/mathfacpub/5
RESEARCH ARTICLE
Using Survival Analysis to Identify Risk
Factors for Treatment Interruption among
New and Retreatment Tuberculosis Patients
in Kenya
Enos O. Masini1, Omar Mansour2*, Clare E. Speer2, Vittorio Addona2, Christy L. Hanson2,
Joseph K. Sitienei1, Hillary K. Kipruto3, Martin Muhingo Githiomi1, Brenda
Nyambura Mungai4
1 Ministry of Health, Nairobi, Kenya, 2 Macalester College, St. Paul, Minnesota, United States of America,
3 World Health Organization, Nairobi, Kenya, 4 Centre for Health Solutions, Nairobi, Kenya
* omar.mansour19@gmail.com
Abstract
Despite high tuberculosis (TB) treatment success rate, treatment adherence is one of the
major obstacles to tuberculosis control in Kenya. Our objective was to identify patient-
related factors that were associated with time to TB treatment interruption and the geo-
graphic distribution of the risk of treatment interruption by county. Data of new and retreat-
ment patients registered in TIBU, a Kenyan national case-based electronic data recording
system, between 2013 and 2014 was obtained. Kaplan-Meier curves and log rank tests
were used to assess the adherence patterns. Mixed-effects Cox proportional hazards
modeling was used for multivariate analysis. Records from 90,170 patients were included
in the study. The cumulative incidence of treatment interruption was 4.5% for new patients,
and 8.5% for retreatment patients. The risk of treatment interruption was highest during the
intensive phase of treatment. Having previously been lost to follow-up was the greatest
independent risk factor for treatment interruption (HR: 4.79 [3.99, 5.75]), followed by being
HIV-positive not on ART (HR: 1.96 [1.70, 2.26]) and TB relapse (HR: 1.70 [1.44, 2.00]).
Male and underweight patients had high risks of treatment interruption (HR: 1.46 [1.35,
1.58]; 1.11 [1.03, 1.20], respectively). High rates of treatment interruption were observed in
counties in the central part of Kenya while counties in the northeast had the lowest risk of
treatment interruption. A better understanding of treatment interruption risk factors is nec-
essary to improve adherence to treatment. Interventions should focus on patients during
the intensive phase, patients who have previously been lost to follow-up, and promotion of
integrated TB and HIV services among public and private facilities.
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Background
Kenya had an 88.3% treatment success rate in 2014 among new and relapse cases of tuberculo-
sis (TB). Ninety-five percent of TB patients knew their HIV status, and 87% of HIV-positive
TB patients were on antiretroviral therapy (ART) [1]. Although these rates are continuing to
improve, TB is a leading cause of death and morbidity in Kenya. It is still considered a “high
burden” country, with approximately 88,000 new cases of TB in 2014. There were 9,400 deaths
among the TB-infected population and 8,100 deaths among those infected with both TB and
HIV [2]. With a national strategic plan and improving methods of data collection,Kenya is
taking steps to reduce rates of infection and death from TB. Nevertheless, a significant popula-
tion of TB patients in Kenya is lost to follow-up at some point during treatment.
This means that such patients do not complete the full regimen necessary to cure them of
the disease.
It is worth noting that the loss to follow-up rate has been declining in the last decade from
10% in 2005–2006 to 5% in 2014 [3,4].
Several previous studies have attempted to identify major factors that affect adherence to
treatment among TB patients. Structural factors including poverty and gender, patients’
beliefs and attitudes towards treatment, the social environment, and the accessibility of health
care services are among the most important factors [5–7]. A study conducted in Nairobi
between 2006 and 2008 found that treatment interruption was observedmost frequently
within the first couple of months of treatment, which is the most intensive period. In addi-
tion, the study found higher rates of treatment interruption among HIV-positive patients,
those who suffer from alcohol dependence, those with a lack of knowledge about TB treat-
ment, and low-income patients [8].
TIBU is a nationwide electronic database created by Kenya’s National Tuberculosis, Lep-
rosy and Lung Disease Program (NTLD) and is the first such data recording system in the
region. TIBU is the Swahili word for treat, and is an acronym for Treatment Information
from Basic Unit. The system was launched in September 2012. It has been used by Kenya’s
Ministry of Health to retrospectively input data from before 2013 and for live capture of all
patients diagnosed from 2013 onward. TIBU’s purpose is to continually update these elec-
tronic health records to allow for immediate analyses of success in disease treatment and pre-
vention. It has yielded a robust database with comprehensive patient parameters over the last
few years. Detailed information about TIBU can be accessed at http://nltp.co.ke/the-tibu-
initiative/ [9].
In logistic regression, the response variable is a binary outcome. However, the ambitious tar-
get of ending the TB epidemic by 2030 proposed by the Sustainable Development Goals of the
United Nations warrants a more granular analysis of TB treatment interruption [10]. Survival
analytic techniques are used to study the time until an event occurs. This allows us to treat as
right-censored those observationswhich result in an outcome other than the endpoint of inter-
est. That is, observations for which the time to event is incomplete. For example, patients could
move to another country or transfer from one reporting system to another. Furthermore, sur-
vival analytic techniques have been commonly used to investigate the association between time
to a certain event and other factors in public health studies, and not predominantly time to
death [11]. This study therefore uses survival analysis to examine the time to treatment inter-
ruption and its relationship to other patient-related factors in order to help guide future
research and policy. In addition to providing this new approach to the problem of treatment
interruption, this is the first study of TB in Kenya to compute a national risk of treatment inter-
ruption as well as county-specific risks.
Tuberculosis Treatment Interruption in Kenya
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Data and Methods
Study population
Data recorded in TIBU from June 2013 to June 2014 of all cases, including smear positive and
smear negative pulmonary (PTB) and extrapulmonary (EPTB), were considered for this analy-
sis (n = 91,049). Most patient-level covariates available in TIBU were obtained and recatego-
rized for the purpose of this analysis: sex, age, patient type, bodymass index (BMI), HIV
status, nutritional support, sector, directly observed therapy (DOT), and the county where
patients received care. The covariates included in the study represent information that was col-
lected and recorded as a single baseline entry when a patient is diagnosed.Due to the newness
of TIBU, most patients’ information does not get updated through the course of treatment.
The BMI of patients who have a BMI below 12.5 kg/m2 and above 42.5 kg/m2 was classified
as unknown due to an apparent recording error. Patients were categorized into four groups
based on their BMI: underweight (<18.5 kg/m2), normal (18.5–25 kg/m2), overweight (25–30
kg/m2), and obese (30 kg/m2).
Patient type has two levels: new patients and retreatment patients. In Kenya, patients who
have never been treated for TB or have taken anti-TB drugs for less than one month are consid-
ered new patients. On the other hand, patients who have previously been treated for TB for
more than one month are considered retreatment patients. Retreatment patients are divided
into four different groups in TIBU: relapse, treatment after failure, treatment after loss to fol-
low-up, and other retreatment patients. Case definitions for retreatment were adopted from
Definitions and Reporting Framework for Tuberculosis by World Health Organization [12].
The Kenya TB treatment guidelines state that all new TB patients should receive the 6-month
regimen and retreatment patients receive the 8-month regimen. The 8-month regimen consists
of two months of Streptomycin (S), Rifampicin (R), Isoniazid (H), Pyrazinamide (Z), Etham-
butol (E) followed by one month of RHZE and then five months of RHE (abbreviated
2SRHZE/1RHZE/5RHE).The first three months of the 8-month regimen are referred to as the
intensive phase while the remaining five months are referred to as the continuous phase. The
6-month regimen consists of taking RHZE for the first two months and then RH for the follow-
ing four months (abbreviated 2RHZE/4RH). The first two months of the 6-month regimen are
referred to as the intensive phase while the remaining four months are referred to as the contin-
uous phase. Patients were considered lost to follow-up if they did not start treatment after diag-
nosis or their treatment was interrupted for two consecutivemonths or more.
HIV status was categorized as: HIV-negative, HIV-positive on ART, or HIV-positive not on
ART. Nutritional support was divided into four categories: caloric support (food support), non-
caloric support (counseling and micronutrients), caloric and non-caloric support, and no nutri-
tional support. Nutritional support is allocated to patients loosely based on their BMI.NTLD
policy states that patients who have a BMI below 18.5 should, at the very least, receive caloric
support. However, the BMI cutoff for caloric support is occasionally lowered to 16 when
resources are limited. However, some private facilities and non-governmental organizations pro-
vide nutritional support to all of their patients. Sector refers to the type of health facility where
the patient was diagnosed and entered into TIBU. It includes public facilities, private facilities,
prisons, and faith-based facilities. DOTwas divided into three categories: family-based (house-
hold member, relative, or friend), community volunteer (CV), or healthcare worker (HCW).
Treatment outcomes and censoring
TB patients were categorized into six different groups according to their treatment outcome in
TIBU: cured, treatment completed, treatment failed, died, lost to follow-up, and transferred
Tuberculosis Treatment Interruption in Kenya
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out. For the purposes of our analysis, only the times for patients who were lost to follow-up
were treated as exact times; for all other outcomes, times were regarded as right-censored.
Treatment duration was determined by calculating the difference in days between date of
treatment initiation and date of treatment termination. New cases for which the observed treat-
ment duration exceeded 180 days were excluded from this analysis because of apparent record-
ing issues and the inability to estimate the timing of treatment interruption. Similarly,
retreatment cases for which the observed treatment duration exceeded 240 days were excluded.
Statistical analysis
All analyses were conducted using the R programming language [13]. Kaplan-Meier curves
were used to display the probability of treatment interruption over time for each risk factor, the
predictors included in TIBU. For brevity, Kaplan-Meier graphs that yielded insignificant log-
rank test p-values at the 5% level were omitted, but available upon request from the authors.
Thus, the survival curves included represent each risk factor which showed a statistically signif-
icant association with time to treatment interruption. In order to explore continuous covariates
and multivariate models, we also constructedCox proportional hazards models for time to
treatment interruption. Our Cox models were mixed-effectsmodels in that they incorporated
both fixed effects, and accounted for the geographic region of Kenya via a random effects com-
ponent. We present the results of our Cox models by reporting hazard ratios (HR) and the cor-
responding 95% confidence interval, along withWald test p-values. To visualize the random
effects component, we present a map of Kenya with each county colored according to the mag-
nitude of its random effects coefficient.The proportionality of hazards assumption made in
our Cox models was examined for all risk factors. None of the risk factors were deemed to vio-
late the proportional hazards assumption. Only complete cases were included in the Cox pro-
portional hazards models (cases with missing values were excluded from the analysis).
The study was approved by the Kenyan Ministry of Health, Nairobi, Kenya. No individual
identifiers were reviewed as part of this analysis.
Results
Records from 90,170 patients were included in the analysis. Approximately, 90% of the patients
were new, 60% were male, 50% were underweight, and 35% were HIV-positive. Among HIV-
positive patients, 87% were on ART. More than 50% of patients were between 15 and 36 years
old, less than 10% under the age of 15, and 6% were above 62 years old. Furthermore, the
majority of patients received care either at a public or private facility (78% and 20%, respec-
tively). Most patients had family-basedDOTwhile a small proportion of patients received
DOT from healthcare workers (87.5% and 11.7%, respectively). Thirteen percent of patients
did not receive any form of nutritional support, 63.6% received only non-caloric support, 7%
received only caloric support, and 16.5% received both (Table 1).
Treatment interruption rate was highest among those who had previously been lost to fol-
low-up (19.7%). In addition, treatment interruption rate was higher among males compared to
females (5.4% and 3.7%, respectively). HIV-positive patients not on ART and those who were
not tested for HIV had higher treatment interruption rates than those who were HIV-negative
or HIV-positive on ART (Table 1).
The cumulative incidence of treatment interruption was 4.5% for new patients, and 8.5% for
retreatment patients. For both patient types, the cumulative incidence increasedmore rapidly
during the first two to three months of treatment (Figs 1 and 2). This is reflected by the hazard
function plots (Figs 3 and 4). The hazard of treatment interruption was highest for both patient
types during the intensive phase. The hazard then decreased notably for both groups over the
Tuberculosis Treatment Interruption in Kenya
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Table 1. Characteristics of TB population in TIBU.
Risk Factor Cured N (%) Completed N (%) Failed N (%) Died N (%) lost to follow-up N (%) Transferred out N (%) Total N (%)
Patient type
New 29,045 (35.6) 41,544 (51.0) 368 (0.5) 4,985 (6.1) 3,568 (4.4) 1,991 (2.4) 81,600 (90.5)
Relapse 2,357 (38.8) 2,520 (41.5) 78 (1.3) 520 (8.6) 386 (6.4) 212 (3.4) 6,091 (6.8)
After failure 174 (74.0) 15 (6.4) 18 (7.7) 9 (3.8) 16 (6.8) 3 (1.3) 240 (0.3)
After loss to follow-up 355 (27.6) 507 (39.5) 10 (0.8) 109 (8.5) 253 (19.7) 50 (3.9) 1,288 (1.4)
Other retreatment 1 (0.1) 766 (80.9) 0 (0.0) 113 (11.9) 42 (4.4) 25 (2.7) 951 (1.0)
TB type
Pulmonary 32,218 (43.1) 32,166 (43.0) 481 (0.6) 4,431 (5.9) 3,588 (4.8) 1,876 (2.6) 74,861 (82.2)
Extrapulmonary 8 (0.1) 13,650 (84.5) 0 (0.0) 1,344 (8.3) 711 (4.4) 445 (2.7) 16,188 (17.8)
Sex
Female 11,500 (31.6) 20,125 (55.3) 136 (0.4) 2,307 (6.3) 1,359 (3.7) 934 (2.7) 36,416 (40.0)
Male 20,726 (38.0) 25,691 (47.0) 345 (0.6) 3,468 (6.4) 2,940 (5.4) 1,387 (2.6) 54,633 (60.0)
Age
Below 15 805 (9.3) 6,921 (80.3) 11 (0.1) 416 (4.8) 288 (3.3) 178 (2.2) 5,514 (9.5)
Between 15 and 27 11,217 (47.0) 9,766 (40.9) 106 (0.4) 785 (3.3) 1,222 (5.1) 761 (3.3) 23,884 (26.2)
Between 28 and 36 9,669 (40.2) 10,886 (45.2) 158 (0.7) 1,429 (5.9) 1,286 (5.3) 651 (2.7) 24,104 (26.5)
Between 37 and 47 6,106 (34.4) 8,990 (50.6) 119 (0.7) 1,325 (7.5) 809 (4.6) 413 (2.2) 17,789 (19.5)
Between 48 and 62 3,311 (29.9) 6,005 (54.1) 66 (0.6) 1,044 (9.4) 456 (4.1) 207 (1.9) 11,115 (12.2)
Above 62 1,114 (20.3) 3,244 (59.0) 21 (0.4) 755 (14.1) 233 (4.2) 111 (2.0) 5,514 (6.1)
BMI
Normal 12,407 (37.8) 16,237 (49.5) 141 (0.4) 1,658 (5.1) 1,463 (4.5) 885 (2.7) 32,833 (44.4)
Underweight 14,939 (41.0) 15,967 (43.8) 271 (0.7) 2,568 (7.0) 1,843 (5.1) 887 (2.4) 36,513 (49.4)
Overweight 891 (25.5) 2,222 (63.7) 5 (0.1) 189 (5.4) 100 (2.9) 83 (2.4) 3,499 (4.7)
Obese 267 (24.7) 715 (66.3) 3 (0.3) 39 (3.6) 34 (3.2) 21 (1.9) 1,082 (1.5)
HIV status
Negative 23,006 (42.2) 25,400 (46.6) 325 (0.6) 2,100 (3.9) 2,478 (4.5) 1,230 (2.2) 54,624 (60.0)
Positive on ART 6,870 (25.0) 15,832 (57.6) 126 (0.5) 2,835 (10.3) 1,116 (4.1) 728 (2.5) 27,530 (30.2)
Positive not on ART 938 (23.4) 2,018 (50.2) 17 (0.4) 537 (13.4) 324 (8.1) 183 (4.5) 4,023 (4.4)
Not tested 1,412 (29.1) 2,566 (52.9) 13 (0.3) 303 (6.2) 381 (7.8) 180 (3.7) 4,872 (5.4)
Sector
Public 26,113 (36.8) 34,697 (48.9) 404 (0.6) 4,645 (6.5) 3,477 (4.9) 1,685 (2.3) 71,118 (78.1)
Private 5,524 (30.3) 10,311 (56.6) 69 (0.4) 1,048 (5.6) 758 (4.2) 507 (2.9) 18,248 (20.0)
Faith-based 77 (30.6) 138 (54.8) 4 (1.6) 20 (7.9) 8 (3.2) 5 (1.9) 253 (0.3)
Prisons 512 (35.9) 670 (46.9) 4 (0.3) 62 (4.3) 56 (3.9) 124 (8.7) 1,430 (1.6)
DOT
Family-based 28,125 (35.4) 40,546 (51.0) 371 (0.5) 4,955 (6.2) 3,612 (4.5) 1,939 (2.4) 79,641 (87.5)
CV 258 (37.2) 324 (46.7) 2 (0.3) 62 (8.9) 36 (5.2) 12 (1.7) 695 (0.8)
HCW 3,827 (36.0) 4,917 (46.3) 108 (1.0) 753 (7.1) 646 (6.1) 367 (3.5) 10,655 (11.7)
Nutritional support
No support 3,775 (33.7) 5,889 (52.6) 39 (0.3) 522 (4.7) 596 (5.3) 371 (3.4) 11,231 (12.9)
Non-caloric 20,016 (36.1) 27,956 (50.4) 288 (0.5) 3,286 (5.9) 2,556 (4.6) 1,375 (2.5) 55,532 (63.6)
Caloric 2,122 (35.1) 3,008 (49.7) 31 (0.5) 435 (7.2) 287 (4.7) 165 (2.8) 6,057 (7.0)
Caloric and non-caloric 5,066 (35.1) 7,071 (49.0) 103 (0.7) 1,274 (8.8) 624 (4.3) 301 (2.1) 14,457 (16.5)
CV: community volunteer; HCW: healthcare worker.
doi:10.1371/journal.pone.0164172.t001
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course of the continuous phase. It is important to note that the initial hazard of treatment
interruption for retreatment patients increasedmore rapidly during the intensive phases com-
pared to new patients.
Retreatment after loss to follow-up patients had the shortest time to treatment interruption,
with all other groups exhibiting similar times to treatment interruption (Fig 5). Male TB
patients had a significantly shorter time to treatment interruption compared to female TB
patients (Fig 6). The pattern holds for new and retreatment patients combined and separately.
Underweight patients have the shortest time to treatment interruption compared to patients
with normal BMI while overweight and obese patients have the longest time to treatment inter-
ruption (Fig 7). HIV patients who are on ART and HIV-negative patients have a noticeably
longer time to treatment interruption compared to HIV-positive patients not on ART and
patients who were not tested for HIV (Fig 8).
Patients who received care at faith-based health facilities had the longest time to treatment
interruption compared to the other facility types (Fig 9). On the other hand, patients who
received care at public facilities had the shortest time to treatment interruption. Patients who
received caloric and non-caloric support combined, along with those receiving only non-calo-
ric support had the longest time to treatment interruption while patients who received only
caloric support had the shortest time to treatment interruption, even compared to patients
who received no form of nutritional support (Fig 10).
Fig 1. Cumulative incidence of loss to follow-up for new patients.
doi:10.1371/journal.pone.0164172.g001
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For both new and retreatment patients, individuals who received DOT from healthcare
workers had longer time to treatment interruption than patients who had family-basedDOT
(Figs 11 and 12). While new patients who receivedDOT for community volunteers had a
shorter time to treatment interruption compared to patients who received either of the other
two forms of DOT, retreatment patients who receivedDOT from community volunteers had a
similar time to treatment interruption as retreatment patients who receivedDOT from health-
care workers and longer time to treatment interruption compared to patients who received
family-basedDOT. However, this pattern is most likely observeddue to the small number of
patients who received DOT from community volunteers, especially among retreatment
patients.
The results of the mixed-effectsCox survivalmodel are summarized in Table 2. Retreatment
patients were more likely to be lost to follow-up than new patients. In particular, those who
had previously been lost to follow-up and relapse patients were more likely to be lost to follow-
up than new patients [HR: 4.79, HR: 1.70, respectively]. There was no difference in the risk of
treatment interruption between patient with EPTB and with PTB. Males were 1.5 times as
likely to be lost to follow-up as females. Children (<15) were notably less likely to be lost to fol-
low-up compared to young adults (15–27) [HR: 0.42]. Similarly, middle-aged (37–47; 48–62)
and old patients (62) were less likely to be lost to follow-up compared to young adults [HR:
Fig 2. Cumulative incidence of loss to follow-up for retreatment patients.
doi:10.1371/journal.pone.0164172.g002
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0.83, HR: 0.74, HR: 0.82, respectively]. The difference in risk of treatment interruption between
adults (28–36) and young adults was not statistically significant (Table 2).
Underweight patients were more likely to be lost to follow-up and overweight patients were
less likely to be lost to follow-up compared to those classified as having normal BMI [HR: 1.11,
Fig 3. Hazard function of loss to follow-up for new patients.
doi:10.1371/journal.pone.0164172.g003
Fig 4. Hazard function of loss to follow-up for retreatment patients.
doi:10.1371/journal.pone.0164172.g004
Tuberculosis Treatment Interruption in Kenya
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Fig 5. Kaplan-Meier plot for TB patient type.
doi:10.1371/journal.pone.0164172.g005
Fig 6. Kaplan-Meier plot for sex (all patients).
doi:10.1371/journal.pone.0164172.g006
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Fig 7. Kaplan-Meier plot for BMI (all patients).
doi:10.1371/journal.pone.0164172.g007
Fig 8. Kaplan-Meier plot for HIV status (all patients).
doi:10.1371/journal.pone.0164172.g008
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Fig 9. Kaplan-Meier plot for sector (all patients).
doi:10.1371/journal.pone.0164172.g009
Fig 10. Kaplan-Meier plot for nutritional support (all patients).
doi:10.1371/journal.pone.0164172.g010
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Fig 11. Kaplan-Meier plot for DOT (new patients).
doi:10.1371/journal.pone.0164172.g011
Fig 12. Kaplan-Meier plot for DOT (retreatment patients).
doi:10.1371/journal.pone.0164172.g012
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HR: 0.79, respectively]. The difference in risk between obese patients and normal patients was
not statistically significant (Table 2). Additionally, the difference betweenHIV-positive
patients on ART and HIV-negative patients was not statistically significant. On the other hand,
HIV-positive patients not on ART and those who had not been tested had a particularly high
risk of treatment interruption compared to HIV-negative patients [HR: 1.96, HR: 1.55, respec-
tively]. Patients who received care at a private facility were less likely to be lost to follow-up
compared to patients who received treatment at a public facility [HR: 0.79]. The difference in
risk between patients who received care at a faith-based facility or prison and patients who
received care at a public facility was not statistically significant. Patients who receivedDOT
from healthcare workers were less likely to be lost to follow-up compared to patients who
received family-basedDOT [HR: 0.85]. However, the difference in the risk between patients
who receivedDOT from community volunteers and those who received family-basedDOT
was not statistically significant. Patients who received caloric nutritional support were more
likely to be lost to follow-up compared to those who received no support [HR: 1.21]. There was
no difference in risk between the other levels of nutritional support and having no nutritional
support.
Three clusters of varying risks of treatment interruption were identified at the county-level
(Fig 13). Most counties with high risk of treatment interruption, compared to the national
average, were located in the central part of Kenya. The counties with the highest risk of treat-
ment interruption were Samburu,West Pokot, and Baringo [HR: 2.9, 2.4, and 2.3, respectively].
Counties in the northeast had lower risk of treatment interruption compared to the national
average. Nyandarua, Wajir, and Mandera had the lowest risk of treatment interruption [HR:
0.5, 0.4, and 0.3, respectively]. The risk of treatment interruption was close to the national aver-
age for the majority of counties in the southwest. It is worth noting that Nairobi had a treat-
ment interruption risk of 1.4.
Discussion
By utilizing survival analytic techniques that account for censoring, this study was able to iden-
tify several patient-level risk factors that are associated with TB treatment interruption in
Kenya. To produce more reliable estimates, we accounted for geographic variability of treat-
ment default rates via a random effects component. The study found that approximately 4.5%
of new patients in Kenya were lost to follow-up, compared with 8.5% of retreatment patients.
In addition, the hazard of default was at its highest during the intensive phase of treatment for
both new and retreatment patients. By analyzing a comprehensive national TB database, our
results can help plan effective future interventions that address TB treatment interruption in
Kenya and in similar settings.
Patients who had previously been lost to follow-up from anti-TB treatment had a signifi-
cantly high risk of being lost to follow-up again [8,14]. This demonstrates that those patients
require special attention once they are captured by the healthcare system to reduce their high
risk of treatment interruption. Considering that patients who received DOT from healthcare
workers were less likely to be lost to follow-up compared to those who received family-based
DOT, patients who have previously been lost to follow-up should be assigned to healthcare
workers for their DOT. On the other hand, there was no difference in the association between
the other two types of DOT, the community volunteering program and the family-basedDOT,
and treatment adherence. It is important to note that before adjusting for other patient covari-
ates, patients who received DOT from healthcare workers were more likely to be lost to follow-
up compared to patients who received family-basedDOT. This is due to the fact that retreat-
ment patients were more likely to receive DOT from healthcare workers compared to new
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Table 2. Survival models results for risk factors associated with treatment interruption.
Unadjusted Model* Adjusted Model†
Risk Factor HR (95% CI) p-value HR (95% CI) p-value
Patient type
New reference reference
Relapse 1.42 (1.27–1.58) <0.0001 1.70 (1.44–2.00) <0.0001
After failure 1.42 (0.86–2.36) 0.17 1.51 (0.87–2.65) 0.15
After loss to follow-up 4.52 (3.96–5.16) <0.0001 4.79 (3.99–5.75) <0.0001
Other retreatment 1.00 (0.73–1.36) 0.99 1.29 (0.87–1.90) 0.20
TB type
Pulmonary reference reference
Extrapulmonary 0.90 (0.82–0.96) 0.01 0.90 (0.80–1.00) 0.51
Sex
Female reference reference
Male 1.46 (1.37–1.57) <0.0001 1.46 (1.35–1.58) <0.0001
Age
Below 15 0.67 (0.59–0.77) <0.0001 0.42 (0.32–0.56) <0.0001
Between 15 and 27 reference reference
Between 28 and 36 1.06 (0.98–1.15) 0.13 1.03 (0.94–1.12) 0.58
Between 37 and 47 0.93 (0.85–1.02) 0.13 0.83 (0.74–0.92) <0.001
Between 48 and 62 0.85 (0.76–0.95) <0.01 0.74 (0.65–0.84) <0.0001
Above 62 0.96 (0.83–1.12) 0.63 0.82 (0.69–0.97) 0.023
BMI
Normal reference reference
Underweight 1.16 (1.08–1.24) <0.0001 1.11 (1.03–1.20) 0.01
Overweight 0.66 (0.54–0.81) <0.0001 0.79 (0.64–0.98) 0.03
Obese 0.69 (0.49–0.98) 0.04 0.89 (0.62–1.28) 0.52
HIV status
Negative reference reference
Positive on ART 0.94 (0.88–1.02) 0.14 0.98 (0.89–1.07) 0.62
Positive not on ART 1.87 (1.66–2.12) <0.0001 1.96 (1.70–2.26) <0.0001
Not tested 1.64 (1.46–1.83) <0.0001 1.55 (1.33–1.81) <0.0001
Sector
Public reference reference
Private 0.80 (0.73–0.87) <0.0001 0.79 (0.71–0.87) <0.0001
Faith-based 0.80 (0.38–1.55) 0.46 0.60 (0.22–1.61) 0.31
Prisons 0.74 (0.55–0.98) 0.03 0.73 (0.53–1.00) 0.05
DOT
Family-based reference reference
CV 1.13 (0.81–1.58) 0.47 0.98 (0.66–1.44) 0.91
HCW 1.43 (1.31–1.56) <0.0001 0.85 (0.73–0.99) 0.03
Nutritional support
No support reference reference
Non-caloric 0.98 (0.89–1.08) 0.72 1.09 (0.96–1.23) 0.17
Caloric 1.03 (0.89–1.20) 0.66 1.21 (1.02–1.44) 0.03
Caloric and non-caloric 1.00 (0.89–1.13) 0.97 1.08 (0.93–1.25) 0.30
*Univariate analysis,
†Multivariate analysis.
HR: hazard ratio; CI: confidence interval; CV: community volunteer; HCW: healthcare worker.
doi:10.1371/journal.pone.0164172.t002
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Fig 13. Map showing the geographic distribution of the risk of default by county.
doi:10.1371/journal.pone.0164172.g013
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patients (80% to 5%, respectively). Nevertheless, more than 25% of those who had previously
been lost to follow-up received family-basedDOT or DOT from community volunteers. The
NTLD should direct more resources toward training additional healthcare workers or look into
measures that could improve the effectiveness of family-basedDOT and the community volun-
teering program. HIV-negative patients and HIV-positive patients on ART had approximately
the same risk of treatment interruption from TB treatment. Conversely, TB patients who were
HIV-positive but not on ART and those who had not been tested for HIV were more likely to
be lost to follow-up than those who were HIV-negative. Considering that 95% of TB patients
know their HIV status and more than 87% of HIV-positive patients receive ART, those who
were not on ART or did not get tested represent a small proportion of TB patients in Kenya.
This speaks to the success of the NTLD policy of having integrated TB and HIV services.An
example of this is the provider-initiated HIV testing and counseling (PITC) in which all
patients are offered services unless they decide to opt-out [15]. Furthermore, these results con-
firm the success of ART in keeping HIV-positive patients relatively healthy and improving TB
treatment outcome [16,17].
Men had a notably higher risk for treatment interruption than women. This trend has been
observed in studies of TB in other countries and has been attributed to men having higher
employment rates and being less likely to seek healthcare after the onset of possible TB symp-
toms [5,14,18]. In Kenya, men are more likely to be employed compared to women, and it has
been observed that TB patients who are employed have work-related issues that influence treat-
ment adherence such as difficulty in obtaining sick leave for treatment and fear of losing work
or dismissal [18–20]. Similarly, the age groups with the highest risk of treatment interruption
were patients of working age, particularly young adults. The groups with the lowest risk of treat-
ment interruption compared to young adults were children and seniors, those least likely to be
following a work schedule. A common suggestion to address default among working patients is
to change clinics’ operating hours so that working patients can access their services at more con-
venient times, while another possibility would be to provide DOT at the workplace [21,22].
While our results indicate that patients who received care at private health facilities were
less likely to be lost to follow-up, they do not necessarily reflect a lower quality of care provided
by the public sector. In Kenya, TB care is provided for free by the public sector while patients
have to cover their treatment costs at private facilities [23]. This couldmean that the socio-eco-
nomic status or other inherent characteristics of those who seek care in the private sector are
different than those who seek care in the public sector. Additionally, all health facilities are
required to report newly detected TB cases to the NTLD. However, not all private facilities
report their cases. Those who report cases are, simply by the nature of their reporting, showing
themselves to be more in compliance with national standards. As such, this finding cannot be
extrapolated to represent the entire private sector. The NTLD should continue promoting pri-
vate–public partnerships to increase the number of private providers integrated into TIBU.
Patients with low BMI had higher risk of treatment interruption than those with normal
BMI. This was expected, as poor treatment outcomes are associated with malnourishment.
Approximately 50% of TB patients in TIBU were malnourished. One measure to mitigate the
effects of malnourishment on treatment adherence is to provide nutritional support. However,
most forms of nutritional support were not associated with the risk of treatment interruption.
Although our results indicate that caloric support was associated with higher risk of treatment
interruption, the underlying relationship is not clear. The evidence on the impact of nutritional
support is conflicting [24–29]. Additionally, we found huge variability in the association
between nutritional support and the risk of treatment interruption across different counties
and sub-populations. The relationship seems to be complex and further research is needed to
evaluate the effectiveness of nutritional support in various settings. Overweight patients had a
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slightly lower risk of treatment interruption compared to those with normal BMI, which could
reflect a higher socioeconomic status.
Finally, there was a large amount of variability in the risk of treatment interruption between
the different counties in Kenya. Generally, arid and semi-arid regions and counties with
nomadic populations, such as Isiolo and Samburu, had the highest risk of treatment interrup-
tion. This could be due to limited access to health facilities or the mobile lifestyle of patients in
these counties. Low risk of treatment interruption was associated with counties that had small
numbers of TB patients, such as Mandera, Wajir, and Garissa. Further research is warranted to
understand the factors contributing to the variability in the risk of treatment interruption
among counties in Kenya.
This study is not without limitations. TIBU includes numerous observationswith recording
errors (e.g., invalid treatment initiation and termination dates and missing information). Also,
the study did not assess the impact of several known TB risk factors such as smoking and dia-
betes.We did not have information on income, which might be a confounding factor in our
analysis. Additionally, we were not able to acknowledge the time-varyingnature of certain
covariates since only baseline values were consistently available from TIBU. It will be impor-
tant to incorporate TB risk factors that are not included in TIBU in future studies. Addressing
treatment interruption could lead to a reduction in the transmission of TB as well as the cost of
providing repeated treatment.
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